Alnylam revenue rises 16.7% as diluted EPS reaches $15.72

what happened

Alnylam Pharmaceuticals reported third-quarter 2026 revenue of $1.46B, up from $1.25B a year earlier, a gain of 16.7%. Net income rose to $2.17B from $292.68M, and diluted earnings per share reached $15.72 compared with $2.14. TradingView published these figures based on the 10-Q filing with the SEC, and noted that its summary is AI-generated and may contain inaccuracies.

For the first nine months, revenue climbed 50% to $3.92B, with product sales up 76%. Collaboration revenue fell 61% because a Roche milestone payment recorded last year did not recur. AMVUTTRA sales grew 65% in the quarter to $1.13B, driven mainly by U.S. demand for the ATTR-CM treatment. ONPATTRO sales dropped 59% over the nine months.

Alnylam expanded the Phase 3 trial of nucresiran in ATTR-CM to about 2,250 patients, completed enrollment in the mivelsiran CAA study, and started a trial of mivelsiran for Alzheimer's disease associated with Down syndrome. The global Phase 3 cardiovascular outcomes trial of zilebesiran is underway. The company expects research, development and commercial spending to rise as programs advance.

why it matters

The quarter shows the company's main drug franchise scaling and turning the business into a profitable one, which matters for investors following biotech stocks. Higher R&D and launch spending may weigh on margins in coming periods, so investors will watch how costs develop alongside sales.

market impact

Alnylam shares: strong revenue and profit support the stock

• ▲Alnylam shares (ALNY) pressure up — revenue and profit growth driven by strong AMVUTTRA demand

tags

instruments